Result 1 - 10 of total 14100
The North American medico-chirurgical review
2023 Volume 3, Issue 6, Page(s) 1131–1133
| Language | English |
|---|---|
| Publishing date | 2023-12-12 |
| Publishing country | United States |
| Document type | Editorial |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
2022 Volume 43, Issue 8, Page(s) e910–e915
Abstract: Abstract: This report summarizes the highlights of a lively discussion between leaders in the cochlear implant (CI) field who also bring significant leadership experience at the practice and health system levels, as well as policy and research ... ...
| Abstract | Abstract: This report summarizes the highlights of a lively discussion between leaders in the cochlear implant (CI) field who also bring significant leadership experience at the practice and health system levels, as well as policy and research perspectives. The discussion revealed several areas in which established patterns of practice should be reconsidered to facilitate wider acceptance of the CI as part of an integrated continuum of hearing healthcare. The importance of continued innovation to advance outcomes, lower cost, and increase access was emphasized. Trends in healthcare funding, which increasingly reward quality at lower cost, will also challenge longstanding assumptions that have influenced program design. Proactive efforts that pursue consistent value in the episode of surgical care while establishing innovative delivery models for audiological and rehabilitation services are the best hope for a future of equitable access and expanding impact. |
|---|---|
| MeSH term(s) | Carum ; Cochlear Implantation ; Cochlear Implants ; Humans |
| Language | English |
| Publishing date | 2022-07-26 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 2036790-9 |
| ISSN | 1537-4505 ; 1531-7129 |
| ISSN (online) | 1537-4505 |
| ISSN | 1531-7129 |
| DOI | 10.1097/MAO.0000000000003643 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 1554: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Journal of thrombosis and haemostasis : JTH
2015 Volume 13, Issue 7, Page(s) 1354–1357
| MeSH term(s) | Biomedical Research/education ; Biomedical Research/history ; Education, Medical/history ; Hematology/education ; Hematology/history ; Hemostasis ; History, 20th Century ; History, 21st Century ; Humans ; Leadership ; Mentors/history ; Societies, Medical/history ; Teaching/history ; Thrombosis/blood ; Thrombosis/history ; United States |
|---|---|
| Language | English |
| Publishing date | 2015-06-11 |
| Publishing country | England |
| Document type | Biography ; Historical Article ; Journal Article ; Portrait |
| ZDB-ID | 2112661-6 |
| ISSN | 1538-7836 ; 1538-7933 |
| ISSN (online) | 1538-7836 |
| ISSN | 1538-7933 |
| DOI | 10.1111/jth.12985 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 5805: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 295: Show issues |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
The Journal of biological chemistry
2015 Volume 290, Issue 30, Page(s) 18833–18842
Abstract: ... tropic Pattern D M-protein strains that also express plasminogen (human Pg (hPg)) binding Group ... A streptococcal M-protein (PAM) as its major cell surface M-protein. SK2a-expressing strains are associated ... with nasopharynx tropicity, and many of these strains express human fibrinogen (hFg) binding Pattern A-C M-proteins ...
| Abstract | Streptokinase (SK), secreted by Group A Streptococcus (GAS), is a single-chain ∼47-kDa protein containing three consecutive primary sequence regions that comprise its α, β, and γ modules. Phylogenetic analyses of the variable β-domain sequences from different GAS strains suggest that SKs can be arranged into two clusters, SK1 and SK2, with a subdivision of SK2 into SK2a and SK2b. SK2b is secreted by skin-tropic Pattern D M-protein strains that also express plasminogen (human Pg (hPg)) binding Group A streptococcal M-protein (PAM) as its major cell surface M-protein. SK2a-expressing strains are associated with nasopharynx tropicity, and many of these strains express human fibrinogen (hFg) binding Pattern A-C M-proteins, e.g. M1. PAM interacts with hPg directly, whereas M1 binds to hPg indirectly via M1-bound hFg. Subsequently, SK is secreted by GAS and activates hPg to plasmin (hPm), thus generating a proteolytic surface on GAS that enhances its dissemination. Due to these different modes of hPg/hPm recognition by GAS, full characterizations of the mechanisms of activation of hPg by SK2a and SK2b and their roles in GAS virulence are important topics. To more fully examine these subjects, isogenic chimeric SK- and M-protein-containing GAS strains were generated, and the virulence of these chimeric strains were analyzed in mice. We show that SK and M-protein alterations influenced the virulence of GAS and were associated with the different natures of hPg activation and hPm binding. These studies demonstrate that GAS virulence can be explained by disparate hPg activation by SK2a and SK2b coupled with the coinherited M-proteins of these strains. |
|---|---|
| MeSH term(s) | Animals ; Antigens, Bacterial/genetics ; Antigens, Bacterial/metabolism ; Bacterial Outer Membrane Proteins/genetics ; Bacterial Outer Membrane Proteins/metabolism ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Carrier Proteins/genetics ; Carrier Proteins/metabolism ; Fibrinogen/genetics ; Fibrinogen/metabolism ; Fibrinolysin/metabolism ; Host-Pathogen Interactions/genetics ; Humans ; Mice ; Plasminogen/genetics ; Plasminogen/metabolism ; Protein Binding ; Streptococcal Infections/genetics ; Streptococcal Infections/metabolism ; Streptococcal Infections/microbiology ; Streptococcus pyogenes/genetics ; Streptococcus pyogenes/metabolism ; Streptococcus pyogenes/pathogenicity ; Streptokinase/genetics ; Streptokinase/metabolism |
| Chemical Substances | Antigens, Bacterial ; Bacterial Outer Membrane Proteins ; Bacterial Proteins ; Carrier Proteins ; plasminogen-binding protein, bacteria ; streptococcal M protein ; Fibrinogen (9001-32-5) ; Plasminogen (9001-91-6) ; Streptokinase (EC 3.4.-) ; Fibrinolysin (EC 3.4.21.7) |
| Language | English |
| Publishing date | 2015-06-12 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, N.I.H., Extramural |
| ZDB-ID | 2997-x |
| ISSN | 1083-351X ; 0021-9258 |
| ISSN (online) | 1083-351X |
| ISSN | 0021-9258 |
| DOI | 10.1074/jbc.M115.655365 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Uc I Zs.108: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2005 Volume 107, Issue 3, Page(s) 880–884
Abstract: ... treated at M.D. Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non ...
| Abstract | To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D. Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3 AML treated during the same period. The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies. Extensive bone marrow fibrosis was found in 23 patients (62%). Poor cytogenetic characteristics were observed in 49% of patients with M7 AML versus 33% of others (P < .001). Complete remission rates were 43% with M7 AML and 57% with non-M7 AML (P = .089). Median overall survival (OS) was 23 and 38 weeks, respectively (P = .006). Median disease-free survivals were 23 versus 52 weeks, respectively (P < .001). By multivariate analysis, M7 AML was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Chromosome Aberrations ; Chromosomes, Human ; Disease-Free Survival ; Female ; Humans ; Leukemia, Megakaryoblastic, Acute/mortality ; Leukemia, Megakaryoblastic, Acute/pathology ; Leukemia, Megakaryoblastic, Acute/therapy ; Male ; Middle Aged ; Multivariate Analysis ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/pathology ; Myelodysplastic Syndromes/therapy ; Neoplasms ; Neoplasms, Second Primary/mortality ; Neoplasms, Second Primary/pathology ; Neoplasms, Second Primary/therapy ; Primary Myelofibrosis/mortality ; Primary Myelofibrosis/pathology ; Primary Myelofibrosis/therapy ; Retrospective Studies |
| Language | English |
| Publishing date | 2005-08-25 |
| Publishing country | United States |
| Document type | Comparative Study ; Journal Article |
| ZDB-ID | 80069-7 |
| ISSN | 1528-0020 ; 0006-4971 |
| ISSN (online) | 1528-0020 |
| ISSN | 0006-4971 |
| DOI | 10.1182/blood-2005-06-2450 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Uh III Zs.140: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 364: Show issues |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Assay and drug development technologies
2003 Volume 1, Issue 1 Pt 2, Page(s) 119–125
| MeSH term(s) | Biomedical Technology ; Genetic Research ; Genome, Human ; Human Genome Project ; Humans |
|---|---|
| Language | English |
| Publishing date | 2003-02 |
| Publishing country | United States |
| Document type | Interview |
| ISSN | 1540-658X |
| ISSN | 1540-658X |
| DOI | 10.1089/154065803321537836 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| 2005 A 2339: Show issues |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2007 Volume 48, Issue 6, Page(s) 1150–1160
Abstract: ... Scoring System commonly used for myelodysplastic syndrome. The M.D. Anderson Prognostic Scoring System ...
| Abstract | Chronic myelomonocytic leukemia continues to be a poorly understood disease, defined by clinical rather than biological features, with no consensus on optimal therapy. In the past, patients were often assessed for risk using scoring systems developed for other diseases, notably the International Prognostic Scoring System commonly used for myelodysplastic syndrome. The M.D. Anderson Prognostic Scoring System, using hemoglobin, absolute lymphocyte count, peripheral blood immature cells, and bone marrow blasts, was developed specifically for CMML; it was based on retrospective analysis of 213 patients. This report re-examines the validity of this scoring system based on follow-up of the initial cohort and prospectively examines its validity in 250 new patients. Both the original MDAPS system and a modified version derived from data of the initial cohort after extended follow-up (substituting lactate dehydrogenase for bone marrow blasts) effectively stratify both patient cohorts by survival and provide a useful risk assessment tool and additional guidance during treatment decisions. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myelomonocytic, Chronic/diagnosis ; Leukemia, Myelomonocytic, Chronic/etiology ; Leukemia, Myelomonocytic, Chronic/mortality ; Leukemia, Myelomonocytic, Chronic/pathology ; Male ; Middle Aged ; Neoplasm Staging/methods ; Prognosis ; Research Design ; Risk Assessment ; Risk Factors ; Survival Analysis |
| Language | English |
| Publishing date | 2007-05-31 |
| Publishing country | United States |
| Document type | Comparative Study ; Journal Article ; Validation Studies |
| ZDB-ID | 1042374-6 |
| ISSN | 1029-2403 ; 1042-8194 |
| ISSN (online) | 1029-2403 |
| ISSN | 1042-8194 |
| DOI | 10.1080/10428190701216386 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2997: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2004 Volume 100, Issue 2, Page(s) 342–349
Abstract: ... of 3.75 or 5.0 mg/m(2) by intravenous bolus daily over a consecutive 3-day period every 3 weeks ...
| Abstract | Background: The goal of the current study was to assess the toxicity, safety, and efficacy of pentostatin in patients with T-cell lymphoid malignancies. Methods: Patients were eligible if they had biopsy-proven T-cell lymphoma or leukemia and failure to respond to previous therapy or an expected complete response rate to conventional therapy of < 20%. Pentostatin was administered at an initial dose of 3.75 or 5.0 mg/m(2) by intravenous bolus daily over a consecutive 3-day period every 3 weeks. Results: Forty-two of 44 patients enrolled in the study were evaluable. The median age of the patients was 62 years (range, 38-86 years). Patients received a median of 3 previous therapies (range, 0-10 previous therapies). Of these patients, 32 (76%) had mycosis fungoides/Sézary syndrome and 10 patients (24%) had other T-cell leukemias or lymphomas. The overall response rate was 54.8% (complete remission, 6 patients [14.3%]; partial remission, 17 patients [40.5%]). Durable responses were observed mainly in patients with Sézary syndrome or peripheral T-cell lymphoma. The median follow-up period for surviving patients was 20 months (range, 1-83+ months). The median duration of response was 4.3 months (range, 1-61 months). The most common toxicities were neutropenia, nausea, and CD4 suppression. A transient early "flare" of disease was observed in some responders. Conclusions: At these doses, pentostatin was reasonably well tolerated and is an effective drug for the treatment of T-cell lymphomas. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Antibiotics, Antineoplastic/adverse effects ; Antibiotics, Antineoplastic/therapeutic use ; Disease-Free Survival ; Drug Administration Schedule ; Enzyme Inhibitors/therapeutic use ; Female ; Humans ; Leukemia, T-Cell/drug therapy ; Lymphoma, T-Cell/drug therapy ; Middle Aged ; Pentostatin/adverse effects ; Pentostatin/therapeutic use ; Treatment Outcome |
| Chemical Substances | Antibiotics, Antineoplastic ; Enzyme Inhibitors ; Pentostatin (395575MZO7) |
| Language | English |
| Publishing date | 2004-01-15 |
| Publishing country | United States |
| Document type | Clinical Trial ; Clinical Trial, Phase II ; Journal Article |
| ZDB-ID | 1429-1 |
| ISSN | 1097-0142 ; 0008-543X ; 1934-662X |
| ISSN (online) | 1097-0142 |
| ISSN | 0008-543X ; 1934-662X |
| DOI | 10.1002/cncr.11899 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Uh III Zs.146: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
American journal of hematology
2004 Volume 77, Issue 3, Page(s) 209–214
Abstract: ... SM). This study objective is to evaluate the features and outcome of patients referred to M. D ...
| Abstract | Mastocytosis is characterized by mast cell proliferation that may be limited to the skin (cutaneous mastocytosis) or may involve one or more extracutaneous organs, e.g., the bone marrow (systemic mastocytosis; SM). This study objective is to evaluate the features and outcome of patients referred to M. D. Anderson Cancer Center (MDACC) with SM. A search of the MDACC database from 1944 to 2002 was conducted for patients with SM and review of their clinical charts. Eighteen patients with mastocytosis were identified in the MDACC database; 15 (11 males and 4 females) had SM and available information. Two had associated myelodysplastic syndrome (MDS), and one had acute myeloid leukemia (AML). The median age was 58 years (range 31-80). Nine patients were treated with subcutaneous interferon-alpha, and only 1 experienced temporary control of the disease. Three of these patients were then treated with imatinib mesylate: transient improvement was noted in two patients. One patient underwent stem cell transplantation as first therapy and achieved complete remission; this patient had associated MDS and is now in complete remission for 8 years. The patient with associated AML was treated with high-dose cytarabine and idarubicin; he has been in complete remission for 16 months. One patient was treated with induction chemotherapy consisting of high-dose cytarabine and 2CDA but expired due to sepsis. Three patients received symptomatic therapy only; these were the only 3 patients who presented with normal blood counts. SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzamides ; Cladribine/therapeutic use ; Combined Modality Therapy ; Cytarabine/administration & dosage ; Female ; Humans ; Idarubicin/administration & dosage ; Imatinib Mesylate ; Interferon-alpha/administration & dosage ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/therapy ; Male ; Mastocytosis, Systemic/drug therapy ; Mastocytosis, Systemic/therapy ; Middle Aged ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/therapy ; Piperazines/administration & dosage ; Prospective Studies ; Pyrimidines/administration & dosage ; Stem Cell Transplantation ; Treatment Outcome |
| Chemical Substances | Benzamides ; Interferon-alpha ; Piperazines ; Pyrimidines ; Cytarabine (04079A1RDZ) ; Cladribine (47M74X9YT5) ; Imatinib Mesylate (8A1O1M485B) ; Idarubicin (ZRP63D75JW) |
| Language | English |
| Publishing date | 2004-11 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 196767-8 |
| ISSN | 1096-8652 ; 0361-8609 |
| ISSN (online) | 1096-8652 |
| ISSN | 0361-8609 |
| DOI | 10.1002/ajh.20211 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 1251: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Angewandte Chemie (International ed. in English)
2000 Volume 40, Issue 18, Page(s) 3474–3477
| Language | English |
|---|---|
| Publishing date | 2000-11-16 |
| Publishing country | Germany |
| Document type | Journal Article |
| ZDB-ID | 2011836-3 |
| ISSN | 1521-3773 ; 1433-7851 |
| ISSN (online) | 1521-3773 |
| ISSN | 1433-7851 |
| DOI | 10.1002/1521-3773(20010917)40:18<3474::aid-anie3474>3.0.co;2-k |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.